Market and Product Forecasts: Asthma in China - Market set to fragment as novel therapies launch

Dallas, TX -- (SBWIRE) -- 08/10/2012 -- The increasing prevalence of asthma and launch of new therapies will boost the Chinese asthma market (Tier 1 and Tier 2 cities) from $331m in 2012 to $489m by 2021. A number of novel products will increase the product offering on the market, however, with only a fraction of the patient pool market receiving asthma treatment, considerable untapped patient potential will remain.

Features and benefits

- Access Datamonitor’s patient-based asthma market forecast for Chinese Tier 1 and Tier cities, with transparent methodology and clear assumptions.
- Explore the current and future market size of asthma in China and see how pipeline products will impact the market.
- Gain insight into asthma market dynamics in China, and see where untapped market potential remains.
- Understand which factors are driving growth in the Chinese asthma market, and what challenges marketed and pipeline products face.

Highlights

Datamonitor forecasts the Chinese Tier 1 and Tier 2 asthma market to grow from $331m in 2012 to $489m by 2021. Despite this growth, the asthma market will reach only a fraction of its potential. Still, with a growing patient pool, unique market dynamics, and increasing treatment coverage, the asthma market in China is becoming more attractive.

Datamonitor expects that four new therapies will enter the Chinese market over 2012–21, including the first once-daily ICS/LABA combinations and biologic anti-asthmatics. While biologics are clinically attractive, their commercial potential will be held back by their relatively high price and limited patient pool.

Datamonitor estimates that in 2012 Seretide and Singulair topped the market with sales of $59m and $65m, respectively, together capturing 37% of the Chinese market (Tier 1 and Tier 2 cities). Datamonitor forecasts that Seretide will face competition from once-daily ICS/LABAs after 2015, but Singulair will maintain its market dominance.

Your key questions answered

- How large is the current asthma market size in Chinese Tier 1 and Tier 2 cities and how is it expected to change over the next 10 years?
- What restrictions will novel therapies face upon launching in the Chinese asthma market?
- How will current market leaders be impacted by additional product launches?
- What role do Chinese regulations play in asthma market dynamics, and how does this impact product use?

Buy your copy of this report @ http://www.reportsnreports.com/reports/184111-market-and-product-forecasts-asthma-in-china-market-set-to-fragment-as-novel-therapies-launch.html .

List Of Tables

Table: Reimbursement status of main anti-asthmatic drugs in Tier 1 cities, 2009 and 2010
Table: Asthma brand sales in Tier 1 and Tier 2 cities in China ($m), 2012–21

List Of Figures

Figure: Patient-based forecast methodology for asthma in China, 2012
Figure: Total healthcare score in China, by administrative region, 2009
Figure: Number of physicians involved in the survey, Tier 1 and Tier 2 cities, 2012
Figure: Number of physicians involved in the survey, Tier 2 and Tier 3 hospitals, 2012
Figure: Product lifecycles in the EU/US and China, 2012
Figure: Asthma sales in Tier 1 and Tier 2 cities in China ($m), 2012–21
Figure: Asthma sales in in Tier 1 and Tier 2 cities in China, by class ($m), 2012–21
Figure: Asthma market share in Tier 1 and Tier 2 cities in China, by class, 2012–21
Figure: Timeline for major asthma pipeline products launching in China, 2012–21
Figure: Asthma market share of key brands and pipeline asthma products in Tier 1 and Tier 2 cities in China, 2012 and 2021
Figure: Singulair (montelukast; Merck & Co.) forecast sales for asthma in Tier 1 and Tier 2 in China ($m), 2012–21
Figure: Seretide (fluticasone/salmeterol; GlaxoSmithKline) forecast sales for asthma in Tier 1 and Tier 2 cities in China ($m), 2012–21
Figure: Pulmicort (budesonide; AstraZeneca) forecast sales for asthma in Tier 1 and Tier 2 cities in China, 2012–21
Figure: Pei Mei Ta Ni (alpha asarone; Guilin Pharma) forecast sales for asthma in Tier 1 and Tier 2 cities in China, 2012–21
Figure: Symbicort (budesonide/formoterol; AstraZeneca) forecast sales for asthma in Tier 1 and Tier 2 cities in China, 2012–21
Figure: An Sai Ma (doxofylline; Heilongjiang Fuhe Huaxing Pharma) forecast sales for asthma Tier 1 and Tier 2 cities in China ($m), 2012–21
Figure: Relovair (fluticasone furoate/vilanterol; GlaxoSmithKline) forecast sales for asthma in Tier 1 and Tier 2 cities in China, 2012–21
Figure: Xolair (omalizumab; Roche/Genentech/Novartis) forecast sales ($m) for asthma in Tier 1 and Tier 2 cities in China, 2012–21
Figure: QMF149 (mometasone/indacaterol; Novartis) forecast sales for asthma in Tier 1 and Tier 2 cities in China, 2012–21
Figure: Lebrikizumab (Roche/Genentech) forecast sales for asthma in Tier 1 and Tier 2 cities in China, 2012–21

Contact sales@reportsandreports.com for further information.